LEISHMANIASIS
Some Selected Abstracts: | |
1. |
Faria
DR, Gollob KJ, Barbosa J Jr, Schriefer A, Machado PR, Lessa H, Carvalho
LP, Romano-Silva MA, de Jesus AR, Carvalho EM, Dutra WO. Decreased in situ
expression of interleukin-10 receptor is correlated with the exacerbated
inflammatory and cytotoxic responses observed in mucosal leishmaniasis.
Infect Immun. 2005 Dec;73(12):7853-9. Department
of Morphology, Federal University of Minas Gerais, Belo Horizonte, Brazil. Human
infection with Leishmania braziliensis can lead to cutaneous leishmaniasis
(CL) or mucosal leishmaniasis (ML). We hypothesize that the intense tissue
destruction observed in ML is a consequence of an uncontrolled exacerbated
inflammatory immune response, with cytotoxic activity. For the first time,
this work identifies the cellular sources of inflammatory and
antiinflammatory cytokines, the expression of effector molecules, and the
expression of interleukin-10 (IL-10) receptor in ML and CL lesions by
using confocal microscopy. ML lesions displayed a higher number of gamma
interferon (IFN-gamma)-producing cells than did CL lesions. In both ML and
CL, CD4+ cells represented the majority of IFN-gamma-producing cells,
followed by CD8+ cells and CD4- CD8- cells. The numbers of tumor necrosis
factor alpha-positive cells, as well as those of IL-10-producing cells,
were similar in ML and CL lesions. The effector molecule granzyme A showed
greater expression in ML than in CL lesions, while inducible nitric oxide
synthase did not. Finally, the expression of IL-10 receptor was lower in
ML than in CL lesions. Thus, our data identified distinct cytokine and
cell population profiles for CL versus ML patients and provide a possible
mechanism for the development of ML disease through the demonstration that
low expression of IL-10 receptor is present in conjunction with a
cytotoxic and inflammatory profile in ML. |
2. |
Murray
HW, Berman JD, Davies CR, Saravia NG. Advances in leishmaniasis. Lancet.
2005 Oct 29-Nov 4;366(9496):1561-77. Review. Department
of Medicine, Weill Medical College of Cornell University, New York, USA.
hwmurray@med.cornell.edu |
Diagnosis, Diagnostics, Immunodiagnosis &
Immunodiagnostics: |
13885.
Chargui N, Bastien P, Kallel K, Haouas N, Akrout FM, Masmoudi A, Zili J,
Chaker E, Othman AD, Azaiez R, Crobu L, Mezhoud H, Babba H. Usefulness
of PCR in the diagnosis of cutaneous leishmaniasis in Tunisia. Trans R
Soc Trop Med Hyg. 2005 Oct;99(10):762-8. 13886.
Fontes CO, Carvalho MA, Nicoli JR, Hamdan JS, Mayrink W, Genaro O, Carmo
LS, Farias LM. Identification and antimicrobial susceptibility of
micro-organisms recovered from cutaneous lesions of human American
tegumentary leishmaniasis in Minas Gerais, Brazil. J Med Microbiol. 2005
Nov;54(Pt 11):1071-6. 13887.
Guddo F, Gallo E, Cillari E, La Rocca AM, Moceo P, Leslie K, Colby T,
Rizzo AG. Detection of Leishmania infantum kinetoplast DNA in laryngeal
tissue from an immunocompetent patient. Hum Pathol. 2005
Oct;36(10):1140-2. 13888.
Passos S, Carvalho LP, Orge G, Jeronimo SM, Bezerra G, Soto M, Alonso C,
Carvalho EM. Recombinant leishmania antigens for serodiagnosis of
visceral leishmaniasis. Clin Diagn Lab Immunol. 2005 Oct;12(10):1164-7. 13889.
Singh R, Subba Raju BV, Jain RK, Salotra P. Potential of direct
agglutination test based on promastigote and amastigote antigens for
serodiagnosis of post-kala-azar dermal leishmaniasis. Clin Diagn Lab
Immunol. 2005 Oct;12(10):1191-4. 13890.
Theinert SM, Basu R, Forgber M, Roy S, Sundar S, Walden P.
Identification of new antigens in visceral leishmaniasis by expression
cloning and immunoblotting with sera of kala-azar patients from Bihar,
India. Infect Immun. 2005 Oct;73(10):7018-21. 13891.
Van der Meide WF, Schoone GJ, Faber WR, Zeegelaar JE, de Vries HJ, Ozbel
Y, Lai A Fat RF, Coelho LI, Kassi M, Schallig HD. Quantitative nucleic
acid sequence-based assay as a new molecular tool for detection and
quantification of Leishmania parasites in skin biopsy samples. J Clin
Microbiol. 2005 Nov;43(11):5560-6. |
Pathogenesis: |
13892.
Barnett PG, Singh SP, Bern C, Hightower AW, Sundar S. Virgin soil: the
spread of visceral leishmaniasis into Uttar Pradesh, India. Am J Trop
Med Hyg. 2005 Oct;73(4):720-5. 13893.
Padmanabhan PK, Mukherjee A, Singh S, Chattopadhyaya S, Gowri VS, Myler
PJ, Srinivasan N, Madhubala R. Glyoxalase I from Leishmania donovani: a
potential target for anti-parasite drug. Biochem Biophys Res Commun.
2005 Dec 2;337(4):1237-48.
|
Vaccines: |
13894
.
Breton M, Tremblay MJ, Ouellette M, Papadopoulou B. Live
nonpathogenic arasitic
vector as a candidate vaccine against visceral leishmaniasis. Infect
Immun. 005
Oct;73(10):6372-82. |
Therapy: |
13895.
Barratt G, Legrand P. Comparison of the efficacy and pharmacology
of formulations of amphotericin B used in treatment of leishmaniasis.
Curr Opin Infect Dis. 2005 Dec;18(6):527-30. Review. 13896. Bimal S, Singh SK, Das VN, Sinha PK, Gupta AK, Bhattacharya SK, Das P. Leishmania donovani: effect of therapy on expression of CD2 antigen and secretion of macrophage migration inhibition factor by T-cells in patients with visceral leishmaniasis. Exp Parasitol. 2005 Oct;111(2):130-2. 13897.
Olliaro PL, Guerin PJ, Gerstl S, Haaskjold AA, Rottingen JA,
Sundar S. Treatment
options for visceral leishmaniasis: a systematic review of clinical
studies done in India, 1980-2004. Lancet Infect Dis. 2005
Dec;5(12):763-74. Review. 13898. Wasunna MK, Rashid JR, Mbui J, Kirigi G, Kinoti D, Lodenyo H, Felton JM, Sabin AJ, Horton J. A phase II dose-increasing study of sitamaquine for the treatment of visceral leishmaniasis in Kenya. Am J Trop Med Hyg. 2005 Nov;73(5):871-6. |